Form 4: Director Acquires Stock Options at Corvus Pharmaceuticals

Richard van den Broek, a Director at Corvus Pharmaceuticals, acquired 15,000 stock options on June 11, 2026, with an exercise price of $11.60.

Summary

• Richard van den Broek, a Director of Corvus Pharmaceuticals, Inc. (CRVS), was granted 15,000 stock options on June 11, 2026.
• These options have an exercise price of $11.60 per share and are exercisable until June 11, 2036.
• The underlying shares vest 100% on the earlier of the first anniversary of the grant date or the 2027 Annual Meeting of stockholders, provided continuous service as a director.
• The transaction was reported on June 15, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard compensation mechanism for a director, indicating continued engagement rather than a significant financial event.

Positives

• Director acquisition of stock options indicates confidence in the company's future prospects.
• The grant of options aligns the director's interests with those of shareholders.
• Vesting schedule tied to service and a future meeting suggests a commitment to continued involvement.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the stock options is subject to market fluctuations and the company's performance.
• Failure to maintain continuous service as a director could result in forfeiture of unvested options.

Future Outlook

The vesting schedule for the stock options is contingent on continuous service and a future event (2027 Annual Meeting), suggesting an expectation of continued director involvement and company progress.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biopharmaceutical industry to incentivize leadership and align their financial interests with long-term company value creation, especially for companies like Corvus Pharmaceuticals that are often in development stages.

Stakeholder Impact

• Shareholders: The alignment of director incentives with shareholder interests is generally positive.
• Employees: May view director compensation as a sign of company stability and growth potential.
• Management: Reinforces standard compensation practices within the industry.

Next Steps

• Director Richard van den Broek is expected to maintain continuous service to ensure vesting of stock options.
• The company's performance will determine the ultimate value of the acquired options.

Key Dates

Keywords

Corvus Pharmaceuticals, CRVS, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Insider Trading